Answers are grounded in this paper and cite their sources.
Review identifies candidate biomarkers for RA-ILD screening and their clinical implications.
Interstitial lung disease associated with rheumatoid arthritis (RA-ILD) is a common extra-articular manifestation of RA that causes increased morbidity and mortality. Effective screening strategies to detect RA-ILD early are lacking. The use of peripheral blood biomarkers represents a promising opportunity to inform and refine screening and monitoring of RA-ILD. Indeed, a number of peripheral biomarkers have been associated with RA-ILD, including autoantibodies, cytokines/chemokines, acute-phase reactants, extracellular matrix proteins, lung epithelial and surfactant proteins, and genetic variants. More recently, composite panels incorporating combinations of peripheral biomarkers have shown utility in identifying RA-ILD. Future studies informing the optimal use of peripheral biomarkers in the screening, prognostication, and monitoring of RA-ILD are needed to validate their clinical performance, define optimal thresholds, and facilitate their integration into routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Luedders et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: